A potent and highly selective irreversible HER2 inhibitor for treating HER2-driven cancers
Publications
This is some text inside of a div block.
April 18, 2023
.jpg)
Related announcements
Iambic Therapeutics to Present at the 43rd Annual JP Morgan Healthcare Conference
